Pharmacokinetics of a new anti-HIV agent VP-0501 and development of its amino acid prodrug for improving oral bioavailability

Anti-HIV agent VP-0501의 생체이용성 향상을 위한 아미노산 프로드럭 개발 및 약물동태연구

  • Cho, Hee-Jeong (College of Veterinary Medicine, Konkuk University) ;
  • Choi, Kyung-Ae (College of Veterinary Medicine, Konkuk University) ;
  • Sung, Ji-Min (College of Veterinary Medicine, Konkuk University) ;
  • Jeong, Sang-Min (College of Veterinary Medicine, Konkuk University) ;
  • Han, Jin-Soo (College of Veterinary Medicine, Konkuk University) ;
  • Kim, Jin-Suk (College of Veterinary Medicine, Konkuk University) ;
  • Shin, Ho-Chul (College of Veterinary Medicine, Konkuk University)
  • Accepted : 2006.01.15
  • Published : 2006.03.29

Abstract

We have studied pharmacokinetics of a new anti-human immunodeficiency virus (HIV) agent VP-0501 and its amino acid prodrug VP-0501AL which is designed to improve oral bioavailability. After oral administration at 100 mg/kg dose in rats (n = 4), VP-0501 was not detectable in plasma (<50 ng/ml), while after the administration of VP-0501AL, VP-0501 was quantitatively detected, at least for 8 hrs, with Cmax of ca. $2.5{\mu}g/ml$ and AUC of $8hr^{\ast}{\mu}g/ml$. When VP-0501 was intravenously administered at 50mg/kg, this compound appeared at a marginal level in plasma with AUC of $2hr^{\ast}{\mu}g/ml$, $t_{1/2}$ of 2 hr, $C_0$ of $0.7{\mu}g/ml$, and MRT of 3 hr. On the other hand, with intravenous VP-0501AL at the same dose, both the prodrug VP-0501AL and its metabolite VP-0501 appeared comparatively at higher level in the plasma: pharmacokinetic parameters of VP-0501AL including $Vd_{\beta}$, AUC, $t_{1/2,{\beta}}$, $C_0$, $CL_{tot}$, and MRT were ca. 2 L/kg, $70hr^{\ast}{\mu}g/ml$, 2 hr, $180{\mu}g/ml$, 0.7 L/hr/kg, and 1 hr, respectively. These results demonstrate that attachment of amino acid alanine to VP-0501 is an effective approach for improvement of its oral bioavailability. Therefore, VP-0501AL is expected to become a new highly bioavailable and potent anti-AIDS drug candidate/lead compound.

References

  1. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997, 31, 185-191 https://doi.org/10.1177/106002809703100211
  2. Arnold E, Das K, Ding J, Yadav PN, Hsiou Y, Boyer PL, Hughes SH. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des Discov 1996, 13, 29-47
  3. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr Drugs 2000, 2, 373-407 https://doi.org/10.2165/00128072-200002050-00005
  4. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995, 28, 281-290 https://doi.org/10.1016/0166-3542(95)00066-6
  5. Bras AP, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol 2001, 8, 207-211
  6. Dannenfelser RM, He H, Joshi Y, Bateman S, Serajuddin AT. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004, 93, 1165-1175 https://doi.org/10.1002/jps.20044
  7. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006, 147, 1-11 https://doi.org/10.1038/sj.bjp.0706446
  8. Haase AT. Viral gene expression and pathogenesis in three emerging diseases: HIV and AIDS; HTLV-I and HAM/TSP; and HHV-8 and Kaposi's sarcoma. FEMS Immunol Med Microbiol 1997, 18, 301-305 https://doi.org/10.1111/j.1574-695X.1997.tb01059.x
  9. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, et. al. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 1994, 83, 566-570 https://doi.org/10.1002/jps.2600830425
  10. Lin JH, Storey DE, Chen IW, Xu X. Improved oral absorption of L-365,260, a poorly soluble drug. Biopharm Drug Dispos 1996, 17, 1-15 https://doi.org/10.1002/(SICI)1099-081X(199601)17:1<1::AID-BDD934>3.0.CO;2-G
  11. Lorenzi PL, Landowski CP, Song X, Borysko KZ, Breitenbach JM, Kim JS, Hilfinger JM, Townsend LB, Drach JC, Amidon GL. Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-$\beta$-D-ribofuranosyl) benzimidazole Enhance Metabolic Stability in Vitro and in Vivo. J Pharmacol Exp Ther 2005, 314, 883-890 https://doi.org/10.1124/jpet.104.082412
  12. Song X, Vig BS, Lorenzi PL, Drach JC, Townsend LB, Amidon GL. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-($\beta$-D-ribofuranosyl) benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem 2005, 48, 1274-1277 https://doi.org/10.1021/jm049450i
  13. Sridevi S, Chauhan AS, Chalasani KB, Jain AK, Diwan PV. Enhancement of dissolution and oral, bioavailability of gliquidone with hydroxy propyl-betacyclodextrin. Pharmazie 2003, 58, 807-810
  14. Sriram D, Yogeeswari P, Srichakravarthy N, Bal TR. Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett 2004, 14, 1085-1087 https://doi.org/10.1016/j.bmcl.2004.01.007
  15. Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004, 27, 1993-1999 https://doi.org/10.1248/bpb.27.1993
  16. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the threedimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994, 243, 369-387 https://doi.org/10.1006/jmbi.1994.1665
  17. Tashiro K, Ikegawa M, Yabe D, Honjo T. [Anti-HIV-1 genes; genetic restriction of AIDS pathogenesis by gene variants]. Nippon Rinsho 1999, 57, 967-974
  18. Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 2003, 20, 1381-1388 https://doi.org/10.1023/A:1025745824632
  19. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS, et. al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995, 39, 2602-2605 https://doi.org/10.1128/AAC.39.12.2602